Application of Chinese Patent Medicine in the Treatment of Cardiovascular Disease in A Grade Three,Level A Hospital in Beijing Under the Background of Centralized Volume-Based Drug Procurement Policy
OBJECTIVE:To investigate the application status of Chinese patent medicine in the treatment of cardiovascular disease in a Grade three,Level A hospital in Beijing under the background of centralized volume-based drug procurement policy(hereinafter referred to as"volume-based procurement"),so as to provide reference for further promotion of volume-based procurement policy.METHODS:Through the hospital information system,the consumption amount and consumption sum of Chinese patent medicine used for cardiovascular diseases in the hospital before volume-based procurement(from Nov.22nd,2021 to Nov.21st,2022)and after volume-based procurement(from Nov.22nd,2022 to Nov.21st,2023)were collected.Pharmacoeconomic methods were used to calculate defined daily dose systems(DDDs),defined daily cost(DDC),actual cost saving and saving rate of drugs.Comparative analysis of differences before and after implementation were conducted based on the calculation.RESULTS:After volume-based procurement,the DDDs of only two varieties of Chinese patent medicine in the treatment of cardiovascular disease increased by 8.48%to 11.82%,while the DDDs of the remaining varieties decreased by 26.10%to 59.09%.The DDC of all statistical varieties decreased by 8.92%to 76.55%.The actual cost savings ranged from 14 400 yuan to 185 100 yuan,with a cost savings rate of 9.79%to 326.51%.CONCLUSIONS:After volume-based procurement of Chinese patent medicine,cost of Chinese patent medicine for cardiovascular disease in the hospital has been reduced,effectively reducing the economic burden of patients with cardiovascular disease,and correspondingly saving the medical insurance fund,which has played a positive role in further promoting the centralized volume-based drug procurement policy.
万方数据
维普
